Morgan Stanley Reiterates “$41.00” Price Target for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has been given a $41.00 price target by equities researchers at Morgan Stanley in a report issued on Friday, January 5th. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective points to a potential upside of 11.85% from the stock’s current price.

Several other brokerages have also weighed in on PFE. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Friday, December 15th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Barclays set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $38.89.

Pfizer (PFE) traded up $0.12 on Friday, reaching $36.66. 12,152,325 shares of the company were exchanged, compared to its average volume of 15,643,533. The firm has a market cap of $218,070.00, a price-to-earnings ratio of 22.49, a price-to-earnings-growth ratio of 2.44 and a beta of 1.01. Pfizer has a 1-year low of $30.90 and a 1-year high of $37.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the business earned $0.61 EPS. analysts forecast that Pfizer will post 2.59 earnings per share for the current year.

Pfizer announced that its Board of Directors has authorized a stock buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,450 shares of company stock worth $1,065,220. 0.06% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. YHB Investment Advisors Inc. increased its position in shares of Pfizer by 12.1% in the fourth quarter. YHB Investment Advisors Inc. now owns 151,760 shares of the biopharmaceutical company’s stock worth $5,497,000 after acquiring an additional 16,352 shares in the last quarter. USS Investment Management Ltd purchased a new position in shares of Pfizer in the fourth quarter worth approximately $6,718,000. Solaris Asset Management LLC increased its position in shares of Pfizer by 135.0% in the fourth quarter. Solaris Asset Management LLC now owns 15,535 shares of the biopharmaceutical company’s stock worth $563,000 after acquiring an additional 8,925 shares in the last quarter. Gemmer Asset Management LLC increased its position in shares of Pfizer by 16.2% in the fourth quarter. Gemmer Asset Management LLC now owns 39,315 shares of the biopharmaceutical company’s stock worth $1,424,000 after acquiring an additional 5,490 shares in the last quarter. Finally, Oakmont Partners LLC increased its position in shares of Pfizer by 31.6% in the fourth quarter. Oakmont Partners LLC now owns 9,091 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 2,185 shares in the last quarter. 69.75% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Morgan Stanley Reiterates “$41.00” Price Target for Pfizer (NYSE:PFE)” was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/morgan-stanley-reiterates-41-00-price-target-for-pfizer-pfe/1820995.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.